Phase I Study of the Novel Antifungal Agent Dapaconazole (Zilt®) in Healthy Volunteers

1,2T. Gagliano-Jucá, 3A.M.M. Arruda, 4M.F. Sampaio, 5A.G. Lopes and 5,3,4G. De Nucci
1Institute of Biophysics Carlos Chagas Filho/UFRJ, CCS-Bloco G, 21949-900, Rio de Janeiro, RJ, Brazil
2Galeno Research Unit, Latino Coelho St., 1301, Parque Taquaral, 13087-010, Campinas, SP, Brazil
3Faculty of Medical Sciences, State University of Campinas-UNICAMP, P.O. Box 6111, Campinas, SP, Brazil
4Department of Pharmacology, ICB-USP, 05508-900, Sao Paulo, SP, Brazil

Abstract: The study aims to evaluate the tolerability of multiple-dose topical dapaconazole tosylate, a new imidazole antifungal drug, in healthy volunteers. Twenty-four healthy volunteers (12 men) with skin pigmentation classified as I-III in the Fitzpatrick scale enrolled in this open-label, two-treatment study with daily application of 40 mg of dapaconazole for 14 consecutive days. Drug application was monitored by a physician and photographs were taken before and 1 h after application to evaluate possible dermatological reactions. Medical evaluations including physical examination, laboratory tests and electrocardiograms were performed to evaluate possible systemic adverse events. To evaluate systemic dapaconazole absorption blood samples were collected before and 2, 4 and 6 h after products application on the first day of treatment. The same occurred in days 7 and 13, but an extra 24 h sample was collected after application of the products. Dapaconazole plasma levels were measured by high-performance liquid chromatography coupled to tandem mass spectrometry. No volunteers had dermatological reactions to the formulations. Only one blood sample had detectable levels of dapaconazole (0.23 mg L⁻¹). One volunteer presented hypertriglyceridemia (424 mg dL⁻¹) after the 14 days of treatment. Three months after the last dose triglycerides were back to normal range (151 mg dL⁻¹). Dapaconazole 2% (Zilt®) showed a safe adverse event profile for topical application in daily doses of 40 mg for up to 14 days in healthy individuals.

Key words: Pharmacokinetics, skin, bioavailability, topical imidazole

INTRODUCTION

From the beginning of the 20th century until shortly after the Second World War, potassium iodide was the standard treatment for cutaneous fungal infections like tinea and sporotrichosis (Dostrovsky et al., 1960; Ura and Nagashima, 1969). In 1946, the first polyene antifungals were obtained from the fermentation of Streptomyces griseus, which later led to the development of nystatin and amphotericin B (Whiffin et al., 1946). Progress of antifungal drug development has since then lagged behind that of the antibacterial antibiotics. The main reason for this is that, before emergence of HIV/AIDS as a global disease, the incidence of fungal infections was believed to be very low, which prevented extensive investments in this research area (Ghannoum and Rice, 1999).

Until the discovery of the azole antifungal drugs, amphotericin B was the only treatment for disseminated fungal infections. Therefore, the antifungal azole compounds constituted a considerable advance in the treatment of superficial and systemic infections of fungal etiology. The first generation of azoles was developed in the late 1960s and included several imidazole compounds, such as micorazole, clotrimazole and econazole (Botter, 1971; Buchel et al., 1972; Thienpont et al., 1975).

Nowadays, resistance to commonly used antifungals is a significant problem, especially in the nosocomial setting, either in invasive or superficial mycosis (Stemberg, 1994; Rodloff et al., 2011; Faller et al., 2011; Canton et al., 2011; Lockhart et al., 2012; Verweij and Warris, 2013). Thus, the emergence of drug-resistant fungal infections has generated the need for new antifungal drugs.

The compound dapaconazole, 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyl(oxycarbonyl))-1H-imidazole, CAS 1269726-67-1, is a novel imidazole derivative and exhibits interesting anti-fungal properties (Table 1) (Kepler et al., 2012). A dose finding study has already been performed in 33 healthy male volunteers. Doses evaluated ranged from 0.5-250 mg (5 g of creams

Corresponding Author: Thiago Gagliano-Jucá, Institute of Biophysics Carlos Chagas Filho/UFRJ, CCS-Bloco G, 21949-900, Rio de Janeiro, RJ, Brazil
with concentrations ranging from 0.01-5% (w/w) applied in single doses to healthy skin. Only 8% of blood samples collected for bioavailability evaluation had detectable levels of dapaconazole. Detections ranged from 0.24-8.0 ng mL\(^{-1}\) (De Moraes et al., 2014). No volunteers had dermatological reactions to any cream concentration evaluated. The present study was designed to evaluate the safety and tolerability of chronic treatment (14 consecutive days) of 2 g of a 2% topical formulation (daily dose of 40 mg) of dapaconazole (Zilt\(^{\text{b}}\)). The study was performed in healthy volunteers of both sexes.

**MATERIALS AND METHODS**

**Reagents:** Cream containing dapaconazole tosylate 2.0% (Zilt\(^{\text{b}}\)) and a formulation containing only vehicle were provided by Biolab Sanus Farmacêutica Ltda. (Brazil). The composition of the vehicle was as follows (w/w): Glycerol 5%, dimethicone 1%, methylparaben 0.18%, propylparaben 0.02%, edetate disodium 0.1%, octyl palmitate 10%, stearic acid 4%, glyceryl stearate/PFG-100 stearate 14%, purified water 65%.

**Human volunteers:** Twenty-four volunteers (twelve men) participated in the study. Their median age was 32 years (19-46 years); mean body weight was 66.5 kg (44.0-93.0 kg), mean height was 165 cm (145-183 cm) and mean Body Mass Index (BMI) was 24.00 kg m\(^{-2}\) (19.63-27.60 kg m\(^{-2}\)). No volunteers had any significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal or hematological diseases, as determined by their medical history, physical examination and routine laboratory tests (hematology, blood biochemistry and urine analysis) and had negative serology for HIV, hepatitis C and B (except for serologic scars). Women were negative for serum \(\beta\)-HCG. Because dermatological reactions are more easily evaluated in subjects with lighter skin pigmentation (Fitzpatrick scale I to III (Fitzpatrick, 1988)) and little body hair, volunteers with these characteristics were selected for the studies. Subjects were instructed to abstain from taking any drug including Over-The-Counter (OTC) medicines for 2 weeks prior to and during the study period. The study was performed according to the revised declaration of Helsinki for biomedical research involving human subjects (WMA, 2008) and the volunteers gave full informed consent. The protocol was approved by the Committee of Research Ethics of the State University of Campinas (UNICAMP), Campinas, Brazil (approval number 474.845).

**Study design:** The study had an open-label, two-treatments (vehicle and Zilt\(^{\text{b}}\)) design. At first, twelve men were treated with Zilt\(^{\text{b}}\) daily for 14 consecutive days. Treatments were performed by topical administration of 2 g of the cream on a fixed area (4 x 4 cm\(^2\)) on the right superior region of the back. Concomitantly with treatments on the right side, volunteers received 2 g of the vehicle on an equivalent area on the left superior region of the back, as a control for possible dermatological reactions to the vehicle. The products were removed 1 h after application. After treatment in men, twelve women were treated with the same administration scheme.

Before enrolment volunteers were tested with the vehicle in order to evaluate any reactions to its components.

**Dermatological evaluation:** Application of the product was performed by a physician and photographic documentation was made of the sites where Zilt\(^{\text{b}}\) (right upper back) and vehicle (left upper back) were applied. Photographs were taken daily before and immediately after the application of the products, as well as before and immediately after product removal (1 h after products administration).

**Dapaconazole bioavailability:** To evaluate systemic bioavailability of dapaconazole following topical application, venous blood samples (7 mL) were collected before and 2, 4 and 6 h after products application on the first day of the study. The same occurred in days 7 and 13, but an extra 24 h sample was collected after application of the products (days 8 and 14, before product administration). Collected blood samples were centrifuged at 2000 g for 10 min, plasma was separated and stored at -20°C until assayed, for pharmacokinetic studies.

---

**Table 1: Minimum Inhibitory Concentration (MIC) of micconazole nitrate and dapaconazole tosylate against various fungal species**

<table>
<thead>
<tr>
<th>Fungal species</th>
<th>Source</th>
<th>CFU mL(^{-1})</th>
<th>Micconazole-N</th>
<th>Dapaconazole-T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspergillus niger</td>
<td>Standard sp.</td>
<td>-</td>
<td>&gt;16.0</td>
<td>8.000</td>
</tr>
<tr>
<td>Microsporum gypseum</td>
<td>Clinical isolate</td>
<td>0.5</td>
<td>0.250</td>
<td>0.125</td>
</tr>
<tr>
<td>Microsporum canis</td>
<td>Clinical isolate</td>
<td>100</td>
<td>0.5</td>
<td>0.250</td>
</tr>
<tr>
<td>Trichophyton verrucosum</td>
<td>Clinical isolate</td>
<td>4700</td>
<td>&gt;16.0</td>
<td>4.000</td>
</tr>
<tr>
<td>Trichophyton rubrum</td>
<td>Clinical isolate</td>
<td>22500</td>
<td>&gt;16.0</td>
<td>4.000</td>
</tr>
<tr>
<td>Trichophyton mentagrophytes</td>
<td>Clinical isolate</td>
<td>2100</td>
<td>0.5</td>
<td>0.250</td>
</tr>
</tbody>
</table>

CFU: Colony formation units, Micconazole-N: Micconazole nitrate, Dapaconazole-T: Dapaconazole tosylate
**Dapaconazole quantification:** Plasma dapaconazole was quantified by high-performance liquid chromatography coupled to tandem mass spectrometry as previously described (De Morais et al., 2014).

**RESULTS**

Twenty-four volunteers received treatment. There were no dermatological reactions, such as dry skin, itching, altered pigmentation or erythema after 14 days of daily exposure to 40 mg of dapaconazole (Fig. 1).

Only one sample of the 294 had detectable levels of dapaconazole (volunteer 14, sample of 6 h of day 13, 0.23 ng mL\(^{-1}\)).

Two adverse events were detected:

- Volunteer 16 presented hypertriglyceridemia (424 mg dL\(^{-1}\)) on the week following the end of the 14 days of treatment. Three months after the last dose triglycerides were back to normal range (151 mg dL\(^{-1}\))
- Volunteer 20 presented low hematocrit (35%) after treatment. This adverse event was considered unrelated to therapy

Volunteers 8, 12 and 24 dropped out due to personal reasons.

**DISCUSSION**

The present study results demonstrated that chronic treatment with 40 mg day\(^{-1}\) of dapaconazole tosylate for 14 days applied to healthy skin can be considered safe in healthy volunteers. This conclusion was based on the absence of local dermatological reactions at the site of the application and the low systemic bioavailability after topical application.

![Fig. 1(a-d): Photographic documentation of possible dermatological reactions in volunteer 3 on day 14 of treatment. Figure show the back of the volunteer, (a) Before and (b) Immediately after the application of the 40 mg daily dose of Zith\(^{®}\) on the right side and placebo on the left side, 1 h after products administration, (c) Before and (d) After products removal](image)
The common dermatological reactions to imidazole antifungals include erythema, dry skin, burning sensation, scaling and pruritus (Leiste et al., 1989; Jegasothy and Pakes, 1991; Suschka et al., 2002; Watanabe et al., 2007; Sharma et al., 2011). These adverse reactions are important factors in securing patient compliance with therapy, a major determinant of the success of the treatment of tinea corporis (Ali et al., 2007; Weinberg, 2009).

A brief review of topical imidazoles available commercially today shows that these antifungal drugs have dermatological reactions as a common adverse event. In a study involving 250 patients with tinea corporis comparing topical treatment with sertaconazole nitrate 2% cream or micizaconazole nitrate 2% cream twice a day for 2 weeks, the main dermatological reactions observed were: Burning in 3 (2.7%) patients receiving sertaconazole and in 2 (1.8%) receiving micizaconazole; pruritus in 2 (1.8%) patients of the sertaconazole group and in 3 (2.7%) of the micizaconazole group and dry skin in 2 (1.8%) patients receiving sertaconazole and in 4 (3.6%) individuals receiving micizaconazole (Sharma et al., 2011). In a similar study evaluating the safety of clotrimazole 1% cream once a day and ketoconazole 2% cream twice a day for four weeks in 106 patients (53 in each group) with tinea pedis, dermatological reactions included burning after application of the product in one patient of each group (1.9%) and redness and scaling of one patient (1.9%) in the group receiving ketoconazole (Suschka et al., 2002). Another study evaluated the safety of the recently developed topical imidazole luliconazole in 224 patients with tinea pedis. Patients received one of the 3 cream formulations evaluated (0.1, 0.5 and 1% luliconazole). The overall safety evaluation showed 2 cases of eczema (0.1 and 1%), 1 case of dermatitis (1%), 1 case of pruritus (0.5%) and 1 case of erythema (0.1%), all considered mild by the authors (Watanabe et al., 2007). In 955 patients treated with 1% oxiconazole nitrate in trials in the United States, the following adverse events were reported: itching (1.6%), burning (1.4%), irritation (0.4%), erythema (0.2%), maceration (0.1%) and fissuring (0.1%) (Jegasothy and Pakes, 1991). A study comparing 2% fluconazole spray once daily versus 1% nafidine spray, once daily for 2-4 weeks, for dermatomycosis had 6% (3/50) of fluconazole-treated patients reporting burning sensations after product application (Leiste et al., 1989). Daily occlusive patch applications of efinaconazole in concentrations up to 10% in healthy volunteers over a three-week period did not significantly change cumulative irritancy indices, when compared with vehicle and control-treated areas (Del Rosso et al., 2013).

Topicalazole drugs have the therapeutic advantage of treating superficial fungal infections without generating high plasma levels of the drug, compared with orally administered azoles and thus show fewer drug interactions (Yu et al., 2005; Galatti et al., 2007; Alexandra et al., 2008; Wey et al., 2008; Broos and van Puijenbroek, 2010). A study with 2% micizaconazole nitrate cream in infants with diaper dermatitis showed that 80% had detectable levels of micizaconazole ranging from 5.2-7.4 mg mL⁻¹ after 7 days of treatment with at least 5 applications per day. This study, however, did not specify the amount of cream (dose) applied at each intervention. No adverse events were noted in the infants with these plasma levels of micizaconazole (Eichenfield and Bogner, 2007). When administered intravaginally, a single-dose of an ovule containing 1200 mg of micizaconazole nitrate generated a mean maximum concentration (Cmax) of 10.7 ng mL⁻¹ (Stevens et al., 2002). A single oral dose of 400 mg of posaconazole generated a mean Cmax of 611 ng mL⁻¹ (Courtney et al., 2003). Oral fluconazole generates plasma levels of 2000 ng mL⁻¹ after a 100 mg dose (DeBruynek, 1997). Thus, dapaconazole plasma levels were much lower than those reported by several studies with topical micizaconazole nitrate, oral posaconazole or fluconazole.

There is no report in the literature of hypertriglyceridermia induced by treatment with topical antifungal azoles. However, orally administered azoles such as ketoconazole and itraconazole are both known to cause hypertriglyceridermia as a commonly reported but low incidence adverse event (Rollman et al., 1985; Tucker et al., 1990; De Lima Barros et al., 2011). Since the volunteer who had elevated triglycerides had no blood samples with a detectable level of dapaconazole, this systemic adverse event is unlikely to be related to the treatment.

CONCLUSION

Because of the absence of dermatological reactions to the formulation and the low systemic bioavailability, Zilt® showed a safe adverse event profile for topical application in daily 40 mg doses for up to 2 weeks in healthy individuals of both sexes. The lack of dermatological reactions also should improve patient compliance during the chronic treatment necessary for many fungal infections of the skin. This study gives support to efficacy evaluations of Zilt®.

ACKNOWLEDGMENT

This study was financially supported by Biolab Sanus Farmacêutica Ltda., Brazil. No authors had any financial relationship with any organizations that might have an interest in the submitted work in the previous 3 years or any other activities that could have influenced the submitted work.
REFERENCES


Watanabe, S., H. Takahashi, T. Nishikawa, I. Takiuchi and N. Higashi et al., 2007. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses, 50: 35-40.


